5002-26-6

Basic information

• Product Name: 4-BROMO-2-METHYLBIPHENYL
• Synonyms: 4-BROMO-2-METHYLBIPHENYL;4-bromo-2-methyl-1,1'-Biphenyl
• CAS NO: 5002-26-6
• Molecular Formula: C₁₃H₁₁Br
• Molecular Weight: 247.13
• EINECS: -0
• Mol File: 5002-26-6.mol

Chemical Properties

• Boiling Point: 113-114°C 0,7mm
• Flash Point: 113-114°C/0.7mm
• Appearance: /
• Density: 1.32g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.6210
• BRN: 1908937
• CAS DataBase Reference: 4-BROMO-2-METHYLBIPHENYL(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-2-METHYLBIPHENYL(5002-26-6)
• EPA Substance Registry System: 4-BROMO-2-METHYLBIPHENYL(5002-26-6)

Safety Data

• Safety Statements: 24/25
• Hazardous Substances Data: 5002-26-6(Hazardous Substances Data)

Usage

Uses

Used in Chemical Industry:
4-Bromo-2-methylbiphenyl is used as a reagent in various chemical syntheses due to its reactivity, which is typical of aryl bromides.
Used in Pharmaceutical Industry:
4-Bromo-2-methylbiphenyl is used as a building block in the synthesis of pharmaceutical compounds, contributing to the development of new drugs and medications. Its reactivity allows for the creation of diverse molecular structures that can be tailored for specific therapeutic applications.

InChI:InChI=1/C13H11Br/c1-10-9-12(14)7-8-13(10)11-5-3-2-4-6-11/h2-9H,1H3

Upstream product

• 71-43-2 benzene 
• 24388-23-6 2-phenyl-4,4,5,5-tetramethyl-1,3,2-dioxoborole 
• 583-75-5 4-Bromo-2-methylaniline 
• 116632-39-4 2-methyl-4-bromoiodobenzene 
• 100-59-4 phenylmagnesium chloride 
• 98-80-6 phenylboronic acid 

Downstream Products

• 230962-03-5 tert-butyl (3R,5E)-3-({[(1S)-2,2-dimethyl-1-({[(1R)-1-phenylethyl]amino}carbonyl)propyl]amino}carbonyl)-6-[(3-methyl-4-phenyl)phenyl]hex-5-enoate 
• 227304-72-5 t-Butyl 4-hydroxy-4-(3-methyl-4-phenylphenyl)piperidine-1-carboxylate 
• 414869-76-4 (R)-2-[2-(tert-butoxy)-2-oxoethyl]-5-(2-methyl-1,1'-biphenyl-4-yl)pentanoic acid cyclohexylammonium salt 
• 414869-73-1 (E)-2-[2-(tert-butoxy)-2-oxoethyl]-5-(2-methyl-1,1'-biphenyl-4-yl)-2-pentenoic acid cyclohexylammonium salt 
• 230961-33-8 N₁-[(1S)-2,2-dimethyl-1-([((1R)-1-(3-pyridyl)ethyl)amino]carbonyl)propyl]-(N₄-hydroxy)-(2R)-2-{3-[3-methyl-(4-phenyl)phenyl]propyl}butanediamide 

Relevant articles and documents

Palladium-catalyzed cross-coupling of aryldiazonium tetrafluoroborate salts with arylboronic esters

A novel palladium-catalyzed reaction of aryldiazonium tetrafluoroborate salts with arylboronic esters furnishes cross-coupled products in moderate yields. The reaction proceeds at relatively mild temperatures and in aqueous media. (C) 2000 Published by Elsevier Science Ltd.

C?I-Selective Cross-Coupling Enabled by a Cationic Palladium Trimer

While there is a growing interest in harnessing synergistic effects of more than one metal in catalysis, relatively little is known beyond bimetallic systems. This report describes the straightforward access to an air-stable Pd trimer and presents unambiguous reactivity data of its privileged capability to differentiate C?I over C?Br bonds in C?C bond formations (arylation and alkylation) of polyhalogenated arenes, which typical Pd0 and PdI-PdI catalysts fail to deliver. Experimental and computational reactivity data, including the first location of a transition state for bond activation by the trimer, are presented, supporting direct trimer reactivity to be feasible.

Asymmetric synthesis of an MMP-3 inhibitor incorporating a 2-alkyl succinate motif

An efficient and practical synthesis is presented of the pharmaceutically active MMP-3 inhibitor UK-370,106 (1) via an olefination/catalytic asymmetric hydrogenation sequence. Commercially available 5-bromo-2-iodotoluene was converted in two steps to the

A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers

The pathology of chronic dermal ulcers is characterized by excessive proteolytic activity which degrades extracellular matrix (required for cell migration) and growth factors and their receptors. The overexpression of MMP-3 (stromelysin-1) and MMP-13 (col

PROCESS FOR PREPARING 4-SUBSTITUTED 2-ALKYLBIPHENYLS AND 2-ALKOXYLBIPHENYLS

A process for preparing 4-substituted 2-alkylbiphenyls and 2-alkoxybiphenyls of the formula (I), by reaction of phenylboronic acids of the formula (II) with 4-bromo- or 4-iodo-alkyl- or -alkoxy-anilines or -anilides of the formula (III) to form compounds of the formula (IV), if appropriate subsequent deacylation to form (V) and subsequent diazotization to form compounds of the formula (VI) and reaction with a nucleophile X, a Cu salt by the Sandmeyer reaction or a reducing agent to give 4-substituted 2-alkylbiphenyls and 2-alkoxybiphenyls of the formula (I).

Matrix metalloprotease inhibitors

Compounds of formula (I): or pharmaceutically acceptable salts thereof, or solvates of either entity, wherein the substituents have the values described herein, are useful as matrix metalloprotease (MMP) inhibitors

Novel liquid crystal compounds and electro-optic devices incorporating them

Liquid crystal compounds of the formula STR1 wherein X can be alkyl (R-), alkoxy (RO-), acyloxy STR2 or alkylcarbonato STR3 wherein R is an alkyl group from 1-10 carbon atoms, and R1 -R3 can be hydrogen, methyl or halogen with the proviso that at least one and no more than two of R1 -R3 are substituents other than hydrogen, have positive dielectric anisotropy and are useful in electro-optic devices which comprise a thin liquid crystal layer between two closely spaced parallel electrodes.